Mary Wilson
Well-known member
August 17, 2022, 4:46 AM CDT
Updated onAugust 17, 2022, 12:09 PM CDT
By Christian Wienberg and Madison Muller
Bavarian Nordic A/S, the only company with an approved vaccine for monkeypox, said it’s no longer certain it can meet demand and is talking to multiple production partners as cases rise across the world.
The Danish company is exploring the possibility of outsourcing some of its production, including a technology transfer to a US contract manufacturer, to meet accelerating demand. Bavarian Nordic “is in conversations with multiple companies to further expand manufacturing capacity globally,” a company spokesperson said in an email.
A move to outsource some production would mark a shift for Bavarian which until now has said it could deliver on all orders from its Danish facility. It also previously said a technology transfer to a third-party -- which would allow bulk manufacturing rather than just ‘fill-finish’ where doses are put into vials and packaging -- would be too cumbersome, expensive and take too long.
“It’s a very dynamic market situation,” Rolf Sass Sorensen, a vice president at the firm, said by phone on Wednesday. “Demand keeps rising and it’s no longer certain that we can continue to meet the demand we’re facing even with the upgrade of our existing manufacturing site in Denmark.”...
https://www.bloomberg.com/news/arti...ne-maker-no-longer-certain-it-can-meet-demand
Updated onAugust 17, 2022, 12:09 PM CDT
By Christian Wienberg and Madison Muller
Bavarian Nordic A/S, the only company with an approved vaccine for monkeypox, said it’s no longer certain it can meet demand and is talking to multiple production partners as cases rise across the world.
The Danish company is exploring the possibility of outsourcing some of its production, including a technology transfer to a US contract manufacturer, to meet accelerating demand. Bavarian Nordic “is in conversations with multiple companies to further expand manufacturing capacity globally,” a company spokesperson said in an email.
A move to outsource some production would mark a shift for Bavarian which until now has said it could deliver on all orders from its Danish facility. It also previously said a technology transfer to a third-party -- which would allow bulk manufacturing rather than just ‘fill-finish’ where doses are put into vials and packaging -- would be too cumbersome, expensive and take too long.
“It’s a very dynamic market situation,” Rolf Sass Sorensen, a vice president at the firm, said by phone on Wednesday. “Demand keeps rising and it’s no longer certain that we can continue to meet the demand we’re facing even with the upgrade of our existing manufacturing site in Denmark.”...
https://www.bloomberg.com/news/arti...ne-maker-no-longer-certain-it-can-meet-demand